Market Overview

UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar Conference

Related AMGN
Emergent BioSolutions Gains on Trial News - Analyst Blog
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Amgen, GSK End Marketing Pact for Osteoporosis Drug (Fox Business)

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $138.00 to $142.00.

In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen. We came away with a greater understanding as to the impact of Biosimilars on AMGN's base biz & have adjusted our model accordingly. We also grew more comfortable in the Biosmilar opp'y for AMGN. We now include a probability adjusted Biosimilar revs beyond 2017 & note net/net biosimilars have a positive NPV to AMGN. Please ask for our Biosimilar APP.”

Amgen closed on Tuesday at $115.46.

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (AMGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free